Noninvasive PET tracking of post-transplant gut microbiota in living mice
暂无分享,去创建一个
Chenran Zhang | Yanpu Wang | Zhaofei Liu | Chenran Zhang | Yang Zhao | Jianhao Lai | D. Lu | Rui Bao | Jianhao Lai | Yang Zhao | Zhaofei Liu | Dehua Lu | Rui Bao | Xun Feng | Ting Zhang | Yanpu Wang | Xun Feng | Ting Zhang
[1] F. Marincola,et al. Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.
[2] Carolyn R Bertozzi,et al. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. , 2009, Angewandte Chemie.
[3] P. Langella,et al. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer , 2016, Journal of Gastroenterology.
[4] Sanjiv S Gambhir,et al. Molecular imaging techniques in body imaging. , 2007, Radiology.
[5] Nicola C. Reading,et al. In vivo imaging and tracking of host–microbiota interactions via metabolic labeling of gut anaerobic bacteria , 2015, Nature Medicine.
[6] E. Warren,et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. , 2006, Blood.
[7] Yuntao Zhu,et al. Selective Imaging of Gram-Negative and Gram-Positive Microbiotas in the Mouse Gut. , 2017, Biochemistry.
[8] H. Akaza,et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. , 1995, European urology.
[9] R. Weissleder. Scaling down imaging: molecular mapping of cancer in mice , 2002, Nature Reviews Cancer.
[10] Y. Aso,et al. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group. , 1992, Urologia internationalis.
[11] Ross A Soo,et al. De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.
[12] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[13] Jennifer A. Prescher,et al. Chemistry in living systems , 2005, Nature chemical biology.
[14] Christopher H. Contag,et al. In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease , 2006, Nature Reviews Immunology.
[15] Steven A. Rosenberg,et al. Raising the Bar: The Curative Potential of Human Cancer Immunotherapy , 2012, Science Translational Medicine.
[16] G. Ren,et al. Imaging of activated T cells as an early predictor of immune response to anti-PD-1 therapy. , 2019, Cancer research.
[17] K. Yarema,et al. Metabolic oligosaccharide engineering: perspectives, applications, and future directions. , 2007, Molecular bioSystems.
[18] M. Atkins,et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.
[19] George Sgouros,et al. Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. , 2016, Cancer research.
[20] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[21] M. Pomper,et al. Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography , 2014, Science Translational Medicine.
[22] I. Durán,et al. Biomarkers of response to PD-1/PD-L1 inhibition. , 2017, Critical reviews in oncology/hematology.
[23] F. Hodi,et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.
[24] R. Weissleder. Molecular imaging: exploring the next frontier. , 1999, Radiology.
[25] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[26] W. Oyen,et al. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. , 2015, Cancer research.
[27] Fan Wang,et al. A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer. , 2015, Biomaterials.
[28] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[29] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[30] Gianni Panagiotou,et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice , 2016, Proceedings of the National Academy of Sciences.
[31] Hannah M. Wexler,et al. Bacteroides: the Good, the Bad, and the Nitty-Gritty , 2007, Clinical Microbiology Reviews.